AzTrials
AzTrials

OsteoarthritisPhase 2ITICNCT00565812

A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee

A Phase 2 study testing SD-6010 in people with Osteoarthritis, run by Pfizer at 183 sites in 14 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. Read more about this study

Who is it for?
Ages 40 to 99 years
Conditions the study is for
Osteoarthritis
What is being tested?
SD-6010
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,457 participants
Where
183 sitesin 14 countries
Study dates
Nov 2007to Nov 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects aged >= 40 years with a BMI >= 25 and <= 40 kg/m2
  • In the past, has been diagnosed with knee OA
  • Radiographic evidence of OA in the study knee

Who cannot join

  • A diagnosis of any other rheumatic disease
  • Current conditions in the study knee that would confound efficacy
  • Selected, traditional clinical safety and laboratory parameters

Trial locations and contacts

183 sites in 14 countries.

183 sites in 14 countries

United States120 sites
  • Ronald Keith Stegemoller, American Health Network

    Avon, Indiana, 46123

  • Advantage Diagnostics

    Beachwood, Ohio, 44122

  • East Penn Rheumatology Associates, PC

    Bethlehem, Pennsylvania, 18015

  • Brookwood Internists, P.C.

    Birmingham, Alabama, 35209

  • Greystone Medical Center

    Birmingham, Alabama, 35242

  • Miray Medical Center

    Brockton, Massachusetts, 02301

  • Kernodle Clinic Inc.

    Burlington, North Carolina, 27215

  • Cadillac Clinical Research, LLC, located at Great Lakes Family Care

    Cadillac, Michigan, 49601

  • Med Center

    Carmichael, California, 95608

  • Rheumatology Associates

    Charleston, South Carolina, 29407

  • Preventive Medicine

    Chicago, Illinois, 60611

  • Rehabilitation Institue of Chicago

    Chicago, Illinois, 60611

  • Mercy Medical Group/Woodlake Research

    Clarkson Valley, Missouri, 63011

  • Rapid Medical Research, Inc.

    Cleveland, Ohio, 44122

  • Columbus Clinical Research, Inc.

    Columbus, Ohio, 43213

  • Optimed Research, LLC

    Columbus, Ohio, 43235

  • College Hospital Costa Mesa

    Costa Mesa, California, 92627

  • NeuroNetwork Trials

    Costa Mesa, California, 92627

  • Baylor Research Institute

    Dallas, Texas, 75231

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • Denver Internal Medicine Group

    Denver, Colorado, 80209

  • Mountain View Clinical Research, Inc.

    Denver, Colorado, 80209

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635

  • Regional Clinical Research, Inc.

    Endwell, New York, 13760

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201

  • Med Investigations, Inc.

    Fair Oaks, California, 95628

  • Advanced Radiology Consultants

    Fairfield, Connecticut, 06824

  • Phase III Clinical Research

    Fall River, Massachusetts, 02720

  • Fall River Clinical Research

    Fall River, Massachusetts, 02721

  • Internal Medicine Associates

    Fargo, North Dakota, 58103

  • Lillestol Research, LLC

    Fargo, North Dakota, 58103

  • Parkway Medical Group

    Fayetteville, Tennessee, 37334

  • Arthritis and Osteoporosis Treatment and Research Center

    Flowood, Mississippi, 39232

  • Southeastern Arthritis Center

    Gainesville, Florida, 32607

  • Southeastern Imaging & Diagnostics

    Gainesville, Florida, 32607

  • Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute

    Gainesville, Florida, 32607

  • NorthShore University HealthSystem

    Glenview, Illinois, 60025

  • New West Physicians Clinical Research

    Golden, Colorado, 80401

  • Southeastern Radiology

    Greensboro, North Carolina, 27407

  • PharmQuest

    Greensboro, North Carolina, 27408

  • Radiant Research, Inc.

    Greer, South Carolina, 29651

  • Clinical Investigation Specialists, Inc.

    Gurnee, Illinois, 60031

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814

  • Jacksonville Center for Clincal Research

    Jacksonville, Florida, 32216

  • Memorial Hospital Jacksonville

    Jacksonville, Florida, 32216

  • Dynamic Clinical Research, Inc.

    Kansas City, Missouri, 64114

  • Joan Prouty Moore, MD

    Kansas City, Missouri, 64114

  • Orthopaedic and Occupational Medicine

    Kansas City, Missouri, 64114

  • The Center for Pharmaceutical Research, P.C.

    Kansas City, Missouri, 64114

  • Clinical Investigation Specialists, Inc.

    Kenosha, Wisconsin, 53142

  • Holston Medical Group

    Kingsport, Tennessee, 37660

  • D. Matthew Sellers MD PC

    Knoxville, Tennessee, 37920

  • Affiliated Clinical Research, Inc.

    Las Vegas, Nevada, 89106

  • Office of Michael Mall, M.D.

    Las Vegas, Nevada, 89109

  • Nevada Imaging Centers

    Las Vegas, Nevada, 89117

  • Nevada Imaging Centers

    Las Vegas, Nevada, 89118

  • Office of Danka Michaels, MD

    Las Vegas, Nevada, 89128

  • Office of Stephen H. Miller, MD

    Las Vegas, Nevada, 89144

  • Office of Manoj Kohli, M.D.

    Lexington, Kentucky, 40517

  • Martin Bowen Hefley Orthopedics

    Little Rock, Arkansas, 72205

  • Teton Research, LLC

    Little Rock, Arkansas, 72205

  • L-MARC Research Center

    Louisville, Kentucky, 40213

  • Lake Health Lyndhurst Clinic

    Lyndhurst, Ohio, 44124

  • Commonwealth Biomedical Research, LLC

    Madisonville, Kentucky, 42431

  • North Georgia Clinical Research

    Marietta, Georgia, 30060

  • Southwind Medical Specialists

    Memphis, Tennessee, 38125

  • Pivotal Research Centers

    Midvale, Utah, 84047

  • Research Institute of the Carolinas, PLLC

    Mooresville, North Carolina, 28117

  • Illinois Bone and Joint Institute, LLC

    Morton Grove, Illinois, 60053

  • Floyd Memorial Hospital

    New Albany, Indiana, 47150

  • HCI Metromedic Walk-In

    New Bedford, Massachusetts, 02740

  • NYU Hospital for Joint Diseases

    New York, New York, 10003

  • BioImaging Technologies, Inc.

    Newtown, Pennsylvania, 18940

  • National Clinical Research - Norfolk, Inc.

    Norfolk, Virginia, 23502

  • Memorial Hospital of Rhode Island

    Pawtucket, Rhode Island, 02860

  • Pivotal Research Centers

    Peoria, Arizona, 85381

  • Arizona Research Center

    Phoenix, Arizona, 85023

  • Pivotal Research Centers

    Phoenix, Arizona, 85027

  • Gold Coast Research, LLC

    Plantation, Florida, 33317

  • Marin E. Hale, M.D., P.A.

    Plantation, Florida, 33317

  • Sabiha Khan, M.D.

    Plantation, Florida, 33324

  • Planters Clinic

    Port Gibson, Mississippi, 39150

  • Rheumatology Associates

    Portland, Maine, 04102

  • National Clinical Research, Incorporated

    Richmond, Virginia, 23294

  • VirtualScopics, Inc.

    Rochester, New York, 14625

  • The Center for Rheumatology and Bone Research

    Rockville, Maryland, 20850

  • Sierra Clinical Research

    Roseville, California, 95661

  • University of California Davis Health System

    Sacramento, California, 95817

  • University of California Davis

    Sacramento, California, 95817

  • PMG Research of Salisbury

    Salisbury, North Carolina, 28144

  • Radiant Research San Antonio Northeast

    San Antonio, Texas, 78217

  • South Texas Radiology Imaging Center

    San Antonio, Texas, 78217

  • Oakwell Clinical Research, LLC

    San Antonio, Texas, 78218

  • Scripps Clinic-Clinical Research

    San Diego, California, 92128

  • Plaza Medical Imaging

    Santa Ana, California, 92704

  • TFD Research, LLC

    Shreveport, Louisiana, 71115

  • The Arthritis Center

    Springfield, Illinois, 62704

  • Advanced Radiology Consultants

    Stamford, Connecticut, 06902

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905

  • Piedmont Healthcare/Research

    Statesville, North Carolina, 28625

  • Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York

    Syracuse, New York, 13210

  • Tacoma Center for Arthritis Research, PS

    Tacoma, Washington, 98405

  • New England Research Associates, LLC

    Trumbull, Connecticut, 06611

  • University of Arizona

    Tucson, Arizona, 85724

  • North Mississippi Medical Center, Inc.

    Tupelo, Mississippi, 38801

  • NorthShore University HealthSystem

    Vernon Hills, Illinois, 60061

  • Advanced Pain Management

    Virginia Beach, Virginia, 23454

  • MedVadis Research Corporation

    Wellesley Hills, Massachusetts, 02481-2106

  • Kanner, Mendelson, Shteinman, LLC

    West Palm Beach, Florida, 33407

  • Radiant Research

    West Palm Beach, Florida, 33407

  • Rheumatology and Endocrinology Specialists of the Palm Beaches, P.A.

    West Palm Beach, Florida, 33407

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Heartland Research Associates, LLC

    Wichita, Kansas, 67205

  • Family Medicine East, Chartered/Radiology

    Wichita, Kansas, 67207

  • Heartland Research Associates, LLC

    Wichita, Kansas, 67207

  • Carolina Arthritis Associates, PA

    Wilmington, North Carolina, 28401

  • PMG Research of Wilmington, LLC

    Wilmington, North Carolina, 28401

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189

  • Fallon Clinic, Inc. (Drug Shipment)

    Worcester, Massachusetts, 01605

  • Fallon Clinic, Inc.

    Worcester, Massachusetts, 01605

Other trials in United States

Czechia14 sites
  • Fakultni nemocnice u sv. Anny v Brne

    Brno, 656 91

  • Revmacentrum MUDr. Mostera, s.r.o.

    Brno-Židenice, 615 00

  • MEDIPONT Plus, s.r.o.

    České Budějovice, 370 01

  • MEDIPONT, s.r.o.

    České Budějovice, 370 01

  • ARTMEDI UPD s r.o.

    Hostivice, 253 01

  • Nemocnice Na Frantisku s poliklinikou

    Prague, 11000

  • Revmatologicky ustav

    Prague, 128 50

  • Centrum pro zdravotnicke zabezpeceni sportovni reprezentace

    Prague, 162 00

  • Ustredni vojenska nemocnice Praha

    Prague, 162 00

  • MSI - Muskuloskeletalni institut

    Prague, 169 00

  • DC Mediscan

    Praha 11 - Chodov, 148 00

  • MediCentrum Praha, a.s.

    Praha 11 - Chodov, 148 00

  • Nemocnice Atlas, a.s.

    Zlín, 760 01

  • PV-Medical s.r.o.

    Zlín, 760 01

Other trials in Czechia

Peru8 sites
  • Hospital Nacional "Alberto Sabogal Sologuren" - Essalud

    Callao, Provincia Constitucional del Callao, Callao-02

  • Clínica San Felipe

    Lima, Lima Province, L-11

  • Hospital Nacional "Edgardo Rebagliati Martins" - Essalud

    Lima, Lima Province, L-11

  • Instituto Peruano del Hueso y la Articulación SAC.

    Lima, Lima Province, L-27

  • Hospital Maria Auxiliadora

    Lima, Lima Province, L-29

  • Centro Medico Corpac

    Lima, Lima Province, Lima-27

  • Centro Empresarial - Altavista Polo 4

    Santiago de Surco, Lima region, Lima 33

  • Instituto de Ginecologia y Reproducción & Cirugia Minimamente Invasiva

    Santiago de Surco, Lima region, Lima 33

Other trials in Peru

Hungary7 sites
  • Orszagos Gerincgyogyaszati Kozpont

    Budapest, 1126

  • Synexus Magyarorszag Kft.

    Budapest, H-1036

  • Heves Megyei Onkormanyzat Markhot Ferenc Korhaz

    Eger, 3300

  • Bekes Megyei Kepviselo-testulet Pandy Kalman Korhaz, Reumatologia

    Gyula, 5700

  • Selye Janos Korhaz, Reumatologiai Szakrendelo

    Komárom, 2900

  • MAV Korhaz es Rendelointezet

    Szolnok, H-5000

  • Veszprem Megyei Onkormanyzat Csolnoky Ferenc Korhaz-Rendelointezet

    Veszprém, H-8200

Other trials in Hungary

Argentina5 sites
  • OMI - Organización Médica de Investigación

    Buenos Aires, C1013AAR

  • Saint Dennis Medical Group S.A.

    Buenos Aires, C1034ACO

  • Investigaciones Reumatológicas y Osteológicas S.R.L.

    Buenos Aires, C1114AAH

  • Instituto Médico Especializado (IME)

    Buenos Aires, C1405BCH

  • IMAI Research

    Buenos Aires, C1425AWC

Other trials in Argentina

Germany5 sites
  • Praxis fuer Orthopaedie, Chirotherapie und Akupunktur

    Bad Hersfeld, 36251

  • Praxis fuer Orthopaedie

    Berlin, 12247

  • Klinische Forschung Berlin-Buch

    Berlin, 13125

  • Praxis Dr. Thomas Jung

    Deggingen, 73326

  • Klinische Forschung Schwerin

    Schwerin, 19055

Other trials in Germany

Russia5 sites
  • Russian State Medical University, Moscow Faculty, City Clinical Hospital #4

    Moscow, 115093

  • Institute of Rheumatology

    Moscow, 115522

  • City Alexandrovskaya Hospital

    Saint Petersburg, 193312

  • L.G. Sokolov Clinical Hospital #122 of Federal Medical-Biology Agency of Russia, Central Polyclinic

    Saint Petersburg, 194291

  • Research Institute of Traumatology and Orthopedy Named After R. R. Vredena

    Saint Petersburg, 195427

Other trials in Russia

Canada4 sites
  • Rheumatology Research Associates Ltd.

    Edmonton, Alberta, T5M 0H4

  • The Arthritis Program Research Group Inc.

    Newmarket, Ontario, L3Y 3R7

  • Centre de Rhumatologie St-Louis

    Sainte-Foy, Quebec, G1W 4R4

  • Nexus Clinic Research

    St. John's, Newfoundland and Labrador, A1A 5E8

Other trials in Canada

Italy3 sites
  • Azienda Sanitaria Genovese, Ospedale La Colletta, Dipartimento Apparato Locomotore

    Arenzano, 16011

  • Presidio Ospedaliero Augusto Murri, Reparto di Reumatologia

    Jesi (Ancona), 60035

  • Ospedale Luigi Sacco, Azienda Ospedaliera Polo Universitario Unita' Operativa di Reumatologia

    Milan, 20157

Other trials in Italy

Poland3 sites
  • NSZOZ "MEDICUS II" S.C. Irena Klimczak, Malgorzata Klimczak, Jerzy Klimczak

    Cieszyn, 43-400

  • "SYNEXUS SCM" Sp. z o.o.

    Wroclaw, 50-088

  • Katedra i Klinika Ortopedii i Traumatologii Narzadu Ruchu

    Wroclaw, 50-556

Other trials in Poland

Slovakia3 sites
  • V. Interna klinika FN a LF UK

    Bratislava, 826 06

  • Ivan Ujvari

    Bratislava

  • Narodny ustav reumatickych chorob

    Piešťany, 921 12

Other trials in Slovakia

Spain3 sites
  • Hospital General Universitario de Guadalajara

    Guadalajara, Guadalajara, 19002

  • Hospital Ntra. Sra. de La Esperanza

    Santiago de Compostela, A Coruña, 15705

  • Hospital Nuestra Señora de Valme

    Seville, Sevilla, 41014

Other trials in Spain

Belgium2 sites
  • Cliniques Universitaires St Luc

    Brussels, 1200

  • Universitair Ziekenhuis Gasthuisberg / Rheumatology

    Leuven, 3000

Other trials in Belgium

Australia1 site
  • Menzies Research Institute

    Hobart, Tasmania, 7000

Other trials in Australia

About this study

Official title: A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study To Investigate The Safety And Efficacy Of Orally Administered SD-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee

The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee osteoarthritis. The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.

Conditions
Osteoarthritis
Being tested
SD-6010, Placebo
Keywords
knee Osteoarthritis Disease Modifying Osteoarthritis Drug
Medical subject headings
Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SD-6010Drug

    200 mg tablets once a day for 2 years

  • SD-6010Drug

    50 mg tablets once a day for 2 years

  • PlaceboDrug

    Placebo tablets once a day for 2 years

Study groups in NCT00565812
Study groupRoleWhat they receive
200 mgActive comparatorHigh dose active comparator
Receives: Drug: SD-6010
50 mgActive comparatorLow dose active comparator
Receives: Drug: SD-6010
PlaceboPlacebo comparatorPlacebo comparator to be used for control purposes
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Progression of Joint Space Narrowing

    Rate of progression of joint space narrowing (JSN) was defined as narrowing in joint space width (JSW) over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in millimeter per year (mm/year) over a 2 year period was used to assess the rate of progression of JSN. Negative values indicating a worsening of osteoarthritis.

    Measured: Baseline up to Month 24

  2. Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Less Than or Equal to (<=) 2

    Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.

    Measured: Baseline up to Month 24

  3. Rate of Progression of Joint Space Narrowing in Participants With Kellgren and Lawrence Grade Equal to (=) 3

    Rate of progression of JSN was defined as narrowing in joint space width over the course of the study. It was measured radiographically in the medial tibiofemoral of knee of participants with OA. The slope reported in mm/year over a 2 year period was used to assess the rate of progression of JSN. KLG system was a method of classifying the severity of knee OA using five grades (0 [no severity] to 4 [maximum severity], higher grade indicating worse knee function). Negative values of slope indicating a worsening of osteoarthritis.

    Measured: Baseline up to Month 24

Secondary outcomes (35)
  1. Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index (WOMAC) Composite Index Score at Month 3, 6, 12, 18 and 24

    The WOMAC was a self-administered, disease-specific instrument which probed clinically important, participant relevant symptoms in the areas of pain, stiffness, and physical function in participants with OA of the knee. The WOMAC composite index was the sum of 24 individual questions regarding subscales of pain, stiffness and physical function (for each item score range: 0 [minimum] to 4 [maximum], higher score indicating worse knee condition). Total score was sum of the 3 subscale scores, giving a possible overall score range of 0 (minimum) to 96 (maximum). Higher score indicating the worse level of pain, stiffness and physical function.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  2. Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Subscale Score at Month 3, 6, 12, 18 and 24

    The WOMAC pain subscale was comprised of 5 questions regarding the amount of pain experienced due to OA in the study knee. The WOMAC pain subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse pain. An overall subscale score range of 0 (minimum) to 20 (maximum), with higher scores indicating more pain.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  3. Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Pain Stiffness Subscale Score at Month 3, 6, 12, 18 and 24

    Stiffness was defined as a sensation of decreased ease in which the participant moved the knee with OA. The WOMAC stiffness subscale was comprised of 2 questions regarding the degree of stiffness experienced in the study knee. The WOMAC stiffness subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse stiffness. An overall score range of 0 (minimum) to 8 (maximum), with higher scores indicating more stiffness.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  4. Change From Baseline in Western Ontario and MacMaster Osteoarthritis Index Physical Function Subscale Score at Month 3, 6, 12, 18 and 24

    The WOMAC physical function subscale referred to the participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale was comprised of 17 questions regarding the degree of difficulty experienced due to OA in the study knee. The WOMAC physical function subscale score for each question ranged from 0 (minimum) to 4 (maximum), higher scores signified worse physical function. An overall score range of 0 (minimum) to 68 (maximum), with higher scores indicating worse physical function.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  5. Change From Baseline in Patient Assessment of Arthritic Pain Visual Analog Scale (VAS) Score at Month 3, 6, 12, 18 and 24

    Pain VAS was a self-administered instrument, a 100 millimeter (mm) line marked by participant. Intensity of pain range (over past week): 0 (mm) =no pain to 100 (mm) =worst possible pain. Higher score indicating severe pain.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  6. Change From Baseline in Patient Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24

    Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using the scale ranging from 1 (minimum) to 5 (maximum), where 1 =very good, 2 =good, 3 =fair, 4 =poor and 5 =very poor. Higher scores indicating worse condition.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  7. Change From Baseline in Physician's Global Assessment of Arthritic Condition Score at Month 3, 6, 12, 18 and 24

    Physician assessed the overall impact of arthritis on the participant's daily life. Participant's condition was rated by the physician using the scale ranging from 1 (minimum) to 5 (maximum), where 1= very good, 2= good, 3= fair, 4= poor and 5= very poor. Higher scores indicating worse condition.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  8. Change From Baseline in Pain After a 50-foot Walk Using Pain Visual Analog Scale Score at Month 3, 6, 12, 18 and 24

    The pain VAS following a 50 foot walk was a single-item, self-administered instrument. Participants were asked to assess the pain due to OA in their study knee after a 50-foot walk. Participants responded on a VAS scale ranging from 0 (no pain) to 100 (severe pain). Higher scores indicating more pain.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  9. Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Total Score at Month 3, 6, 12, 18 and 24

    The OA pain and assessment tool-knee joint is also known as the intermittent and constant osteoarthritis pain (ICOAP) scale. The OA pain assessment tool-knee joint was an 11-item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. The total score was calculated by adding the 11 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse health.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  10. Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Constant Pain Subscale Score at Month 3, 6, 12, 18 and 24

    The OA pain assessment tool-knee joint constant pain subscale was a 5 item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Overall subscale score was calculated by adding the 5 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse constant pain.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  11. Change From Baseline in Osteoarthritis Pain Assessment Tool-Knee Joint Intermittent Pain Subscale Score at Month 3, 6, 12, 18 and 24

    The OA pain assessment tool-knee joint intermittent pain subscale score a 6 item scale, with each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Overall subscale score was calculated by adding the 6 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse intermittent pain.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  12. Change From Baseline in Osteoarthritis Research Society International (OARSI) Knee Function Survey Score at Month 3, 6, 12, 18 and 24

    The OARSI knee function survey was an 11-item scale with each item scored 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. The total score was the sum of the 11 items and ranged from 0 (minimum) to 44 (maximum), where higher scores indicating worse health condition.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  13. Change From Baseline in Knee Injury and Osteoarthritis Outcome Score - Physical Function Short Form (KOOS-PS) Score at Month 3, 6, 12, 18 and 24

    The KOOS-PS was used to rate participant's opinions about the difficulties they experienced with activity due to problems with their knee. It was a 7-item scale, each item scored from 0 (minimum) to 4 (maximum), where 4 indicated worst health condition. Total score was calculated by adding the responses to 7 items and rescaled to a 0 (minimum) to 100 (maximum) scale, where higher scores indicating worse health condition.

    Measured: Baseline, Month 3, 6, 12, 18, 24

  14. Change From Baseline in Short Form-36 (SF-36) Physical Functioning Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 16.18 (minimum) to 57.11 (maximum), with higher scores indicating better physical functioning.

    Measured: Baseline, Month 12, 24

  15. Change From Baseline in Short Form-36 Role - Physical Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 18.45 (minimum) to 56.62 (maximum), with higher scores indicating better role-physical.

    Measured: Baseline, Month 12, 24

  16. Change From Baseline in Short Form-36 Bodily Pain Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 19.23 (minimum) to 60.88 (maximum), with higher scores indicating lower bodily pain.

    Measured: Baseline, Month 12, 24

  17. Change From Baseline in Short Form-36 General Health Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 16.75 (minimum) to 63.72 (maximum), with higher scores indicating better general health.

    Measured: Baseline, Month 12, 24

  18. Change From Baseline in Short Form-36 Vitality Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 22.02 (minimum) to 69.92 (maximum), with higher scores indicating better vitality.

    Measured: Baseline, Month 12, 24

  19. Change From Baseline in Short Form-36 Social Functioning Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 13.38 (minimum) to 56.40 (maximum), with higher scores indicating better social functioning.

    Measured: Baseline, Month 12, 24

  20. Change From Baseline in Short Form-36 Role-Emotional Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 10.25 (minimum) to 55.68 (maximum), with higher scores indicating better role-emotional.

    Measured: Baseline, Month 12, 24

  21. Change From Baseline in Short Form-36 Mental Health Domain Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 8.02 (minimum) to 63.43 (maximum), with higher scores indicating better mental health.

    Measured: Baseline, Month 12, 24

  22. Change From Baseline in Short Form-36 Physical Health Component Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 22.88 (minimum) to 58.69 (maximum), with higher scores indicating better physical health.

    Measured: Baseline, Month 12, 24

  23. Change From Baseline in Short Form-36 Mental Health Component Score at Month 12 and 24

    The SF-36 was a participant administered scale assessing general quality of life. It consisted of self-administered 36-item questionnaire that measured 8 health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. These 8 domains were also summarized as physical and mental component scores. The score for each domain and component score was the mean of the individual question scores, which were scaled from 0 (minimum) to 100 (maximum), where higher scores indicated highest level of health/functioning. Linear transformations were performed to transform scores and rescaled to a score range of 11.11 (minimum) to 61.67 (maximum), with higher scores indicating better mental health.

    Measured: Baseline, Month 12, 24

  24. Number of Participants With EuroQoL-5D (EQ-5D) Mobility Domain Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D mobility domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problem), 2 =moderate health (some problems) and 3 =worst health (confined to bed). Higher scores indicating worse health condition. Participants with EQ-5D mobility domain score were reported in this measure.

    Measured: Baseline, Month 12, 24

  25. Number of Participants With EuroQoL-5D Self-Care Domain Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D self-care domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problems with self-care), 2 =moderate health (some problems) and 3 =worst health (unable to wash or dress). Higher scores indicating worse health condition. Participants with EQ-5D self-care domain score were reported in this measure.

    Measured: Baseline, Month 12, 24

  26. Number of Participants With EuroQoL-5D Usual Activity Domain Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D usual activity domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no problems), 2 =moderate health (some problems) and 3 =worst health state (unable to perform usual activities). Higher scores indicating worse health condition. Participants with EQ-5D usual activity domain score were reported in this measure.

    Measured: Baseline, Month 12, 24

  27. Number of Participants With EuroQo-5D Pain and Discomfort Domain Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. EQ-5D pain and discomfort domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (no pain and discomfort), 2 =moderate health (moderate pain and discomfort) and 3 =worst health state (extreme pain and discomfort). Higher scores indicated worse health condition. Participants with EQ-5D pain and discomfort domain score were reported in this measure.

    Measured: Baseline, Month 12, 24

  28. Number of Participants With EuroQoL-5D Anxiety and Depression Domain Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life. Health state profile component assessed level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. EQ-5D anxiety and depression domain score scale ranged from 1 (minimum) to 3 (maximum), where 1 =better health (not anxious, depressed), 2 =moderate health (moderately anxious, depressed) and 3 =worst health (extremely anxious, depressed). Higher scores indicating worse health condition. Participants with EQ-5D anxiety and depression domain score were reported in this measure.

    Measured: Baseline, Month 12, 24

  29. EuroQoL-5D Visual Analog Scale Score

    The EQ-5D VAS score was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.

    Measured: Baseline, Month 12, 24

  30. Number of Participants With Increase in Total Analgesic Medication Use

    Increase in total analgesic medication use for OA in the study knee was a comparison back to baseline of an increased and sustained use of standard background and/or rescue medication for more than 28 days as measured at the Month 12 and 24 visits. Only medications for OA knee pain were considered.

    Measured: Month 12, 24

  31. Number of Participants With Decrease in Total Analgesic Medication Use

    Decrease in total analgesic medication use for OA in the study knee was a comparison back to baseline of a decreased and irregular use of standard background and/or rescue medication for more than 28 days as measured at the Month 12 and 24 visits. Only medications for OA knee pain were considered.

    Measured: Month 12, 24

  32. Patient Global Impression of Change Score

    Patient global impression of change was a participant-rated instrument that measured change in participant's overall status on a 7-point scale ranging from: 1 =very much improved, 2 =much improved, 3 =minimally improved, 4 =no change, 5 =minimally worse, 6 =much worse and 7 =very much worse. Higher scores indicating worse condition.

    Measured: Month 24

  33. Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index

    The OMERACT-OARSI responder index was used to determine whether participants may be considered responders to treatment. An OMERACT-OARSI responder was a participant who had a better response on the WOMAC pain subscale score, a better response on the WOMAC physical function subscale score or improvement on at least two of the three domains: WOMAC pain subscale score (overall score range of 0 [minimum] to 20 [maximum], higher scores indicating more pain), WOMAC physical function subscale score (overall score range of 0 [minimum] to 68 [maximum], higher scores indicating worse physical function) and patient global assessment of arthritic condition score (overall score range of 1 [minimum] to 5 [maximum], higher scores indicating worse condition). Number of participants who were OMERACT-OARSI responder were reported in this measure.

    Measured: Month 24

  34. Number of Participants With Joint Space Narrowing Progression

    JSN progressor was defined as a participant with a decrease in joint space width that was greater in magnitude than the smallest detectable difference (0.199 mm).

    Measured: Month 24

  35. Number of Participants Applicable for Virtual Joint Replacement

    A virtual joint replacement candidate was defined as a participant whose last two WOMAC pain subscale scores (overall score range of 0 [minimum] to 20 [maximum], higher scores indicating more pain) were at least 8, last two WOMAC physical function subscale scores (overall score range of 0 [minimum] to 68 [maximum], higher scores indicating worse physical function) were at least 28 and was a joint space narrowing progressor (a participant with a decrease in JSW that was greater in magnitude than the smallest detectable difference =0.199 mm).

    Measured: Month 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2007 (estimated)
  2. Study startNov 2007
  3. Primary completionOct 2011
  4. Study completionNov 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
1,457 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00565812
Sponsor's protocol ID
A6171016
Other IDs
2007-001457-26, ITIC
Acronym
ITIC
Status last verified
Nov 2016
First submitted
29 Nov 2007
Last updated
30 Dec 2016
Data monitoring committee
Yes

Publications

  • Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, Abramson SB, Manning PT, Miller CG, Vignon E. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. doi: 10.1136/annrheumdis-2012-202239. Epub 2012 Nov 10.

    PubMed 23144445

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing SD-6010 in people with Osteoarthritis, run by Pfizer at 183 sites in 14 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 183 sites in United States, Czechia, Peru, Hungary, Argentina and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Dec 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Progression of Joint Space Narrowing (time frame: Baseline up to Month 24). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00565812, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2016.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
ITIC Clinical Trial NCT00565812 | AzTrials